Jim Cramer on the Problems With Buying Drug Stocks
Jim Cramer breaks down why it is so difficult to buy drug stocks right now.
Ahead of J.P. Morgan's Healthcare Conference, Jim Cramer discusses the difficulties in buying drug stocks right now.
Cramer says Celgene (CELG) - Get Report is a stock he would historically buy. When it comes to generics, Cramer brings up Teva (TEVJF) cutting numbers. Allergan (AGN) - Get Report is up after selling its generics business.
This article was written by a staff member of TheStreet.
